Rallybio Corporation (NASDAQ:RLYB) Given Average Recommendation of “Reduce” by Brokerages

Rallybio Corporation (NASDAQ:RLYB) has been assigned a consensus rating of “Reduce” from the five ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $40.00.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rallybio in a report on Monday, December 29th.

Rallybio Stock Up 27.5%

Shares of RLYB stock opened at $9.61 on Monday. Rallybio has a fifty-two week low of $1.76 and a fifty-two week high of $10.70. The business has a fifty day simple moving average of $5.36 and a 200-day simple moving average of $5.08. The stock has a market cap of $50.74 million, a P/E ratio of -3.71 and a beta of -1.13.

Institutional Investors Weigh In On Rallybio

A number of large investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its position in Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after buying an additional 2,996 shares in the last quarter. XTX Topco Ltd boosted its stake in shares of Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after acquiring an additional 38,205 shares during the last quarter. Susquehanna International Group LLP boosted its stake in shares of Rallybio by 485.9% during the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after acquiring an additional 113,031 shares during the last quarter. Renaissance Technologies LLC increased its position in Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after purchasing an additional 120,892 shares in the last quarter. Finally, Citadel Advisors LLC raised its stake in Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after purchasing an additional 373,821 shares during the last quarter. Institutional investors and hedge funds own 90.34% of the company’s stock.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.